RecruitingPhase 2NCT07541430

A Study in Adults With Desmoid Tumors

An Open-Label, Multicenter, Single-Arm Phase 2 Study of ES014 in Adult Subjects With Desmoid Tumors

Sponsor

Elpiscience (Suzhou) Biopharma, Ltd.

Enrollment

50 participants

Start Date

Apr 30, 2026

Study Type

INTERVENTIONAL

Conditions

Desmoid Tumor

Summary

This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ES014 and a drug called ES014 for people with desmoid tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.